Read more
Genetics, Neurology, Behavior, and Diet in Parkinson's Disease: The Neuroscience of Parkinson's Disease, Volume 2 provides a single source of material covering different scientific domains of neuropathology underlying this condition. The book covers a wide range of subjects and unravels the complex relationships between genetics, molecular biology, pharmaceutical chemistry, neurobiology, imaging, assessments, and treatment regimens. It fills a much-needed gap as a "one-stop" synopsis of everything to do with the neurology and neuroscience related to Parkinson's disease-from chemicals and cells to individuals. It is an invaluable resource for neuroscientists, neurologists, and anyone in the field.
List of contents
Part I: Genetics, molecular and cellular biology 2. Alpha-synuclein gene and Parkinson's diseaseAthina-Maria Simitsi, Chistos Koros
and Leonidas Stefanis
3. The DJ-1 gene and protein: links with Parkinson's diseaseVanessa J. Musco, Sarah J. Annesley
and Paul R. Fisher
4. Regulation of tyrosine hydroxylase: relevance to Parkinson's diseaseGelareh Alam
and Jason R. Richardson
5. Linking glucocerebrosidase gene (GBA) variants and Parkinson's diseasectoria Berge-Seidl
and Mathias Toft
6. Astrocytes and microglia in Parkinson's disease and animal modelsKatarzyna Kuter
7. The role of autophagy in Parkinson's disease etiopathogenesisEmanuel Candeias, Jãao Duarte Magalhães, Daniel Santos, Helena Costa, Diana F. Silva, Ana Raquel Esteves
and Sandra Morais Cardoso
8. The mitochondrial network in Parkinson's diseaseAndreas Aufschnaiter, Verena Kohler
and Sabrina Büttner
9. Signal transduction in Parkinson's disease: modulation of neurotransmission, symptomatology, and therapyMattia Volta
10. Oxidative stress signaling and regulated cell death in Parkinson's diseaseCarlos Velez-Pardo
and Marlene Jimenez-Del-Rio
11. Subcellular-specific alpha-synuclein in Parkinson's diseaseBenjamin Rosen, Ketan S. Patil, Guido W. Alves
and Simon G. Møller
12. Melanocortin 1 receptor: Parkinson's disease, melanoma risk, and neuroprotectionGemma Tell-Marti, Joan Anton Puig-Butillé
and Susana Puig
13. Energy regulation and Parkinson's diseaseLiting Hang
and Kah-Leong Lim
14. Linking rotigotine, Parkinson's disease, and brain-derived neurotrophic factorKazuhiro Sohya, Kazunori O'Hashi
and Hiroshi Kunugi
Part II: Neurology, physiology and imaging 15. The different syndromes in Parkinson's disease: an overviewNikolaos Giagkou
and Maria Stamelou
16. Neuromolecular imaging in Parkinson's diseasePatricia A. Broderick
and Leslie Wenning
17. Interlinking brain mapping and Parkinson's disease: MRI analysis, nigrosome 1 and nigrosome 4Eung Yeop Kim, Young Hee Sung
and Jongho Lee
18. Interconnecting Parkinson's disease: the use of computed tomography and microelectrode recording in DBS surgeryRyan B. Kochanski
and Sepehr Sani
19. Linking diffusion tensor imaging, microstructures and Parkinson's diseaseYu Zhang, Norbert Schuff, I-Wei Wu
and Duygu Tosun
20. Detecting parkinsonian degeneration in lateroventral tier of substantia nigra pars compacta with MRIJason Langley, Daniel E. Huddleston
and Xiaoping P. Hu
21. Vagal motoneurons in Parkinson's diseaseRuth E. Musgrove, Wei-Hua Chiu
and Joshua A. Goldberg
22. Circadian clock disruption and neuroinflammation in Parkinson's disease: a new perspective Elisabetta Lauretti
and Domenico Praticò
23. Motor cortex stimulation in Parkinson's diseaseAngelo Lavano, Giusy Guzzi, Attilio Della Torre
and Domenico La Torre
24. Action programming disorders associated with Parkinson's diseaseKenneth M. Heilman
25. The striatal medium spiny neurons: what they are and how they link with Parkinson's diseaseFu-Ming Zhou
26. Disruptions of frontostriatal language functions in Parkinson's diseaseAdolfo M. García, Yamile Bocanegra, Agustina Birba, Juan Rafael Orozco-Arroyave, Lucas Sedeño
and Agustín Ibañez
27. Alpha-synuclein and neuroinflammation in Parkinson's diseaseTatiana Varanita
and Luigi Bubacco
28. Tau and its interactions with other proteins in neurodegenerative diseasesKatelyn H. Mroczek, Sarah J. Annesley
and Paul R. Fisher
29. Interaction between brain angiotensin and dopaminergic systems and Parkinson's diseaseJose Luis Labandeira-Garcia, Pablo Garrido-Gil, Maria A. Pedrosa, Carmen M. Labandeira
and Ana I. Rodriguez-Perez
30. Restoring dopamine levels in Parkinson's disease: neuronal pathways, agonists and antiinflammatory agentsÁgatha Oliveira-Giacomelli, C.M. Albino, Hellio Danny Nóbrega de Souza
and Henning Ulrich
Part III: Behaviour and psychopathology 31. Motivation and motivational aspects of Parkinson's diseaseAbdeslam Chagraoui, Emilie Puginier
and Philippe De Deurwaerdère
32. Linking anxiety, cognitive and sensory deficits to gait and balance deficits in Parkinson's diseaseQuincy J. Almeida
33. Motor programs interlinking gait and bradykinesia in Parkinson's diseaseTateo Warabi, Kiyoharu Inoue
and Nobuo Yanagisawa
34. Olfactory disturbances in Parkinson's diseaseLais S. Rodrigues, Juliane Fagotti, Adriano D.S. Targa, Ana Carolina D. Noseda, Jessica L. Ilkiw, Flavia W.C. Dorieux
and Marcelo M.S. Lima
35. Interlinking dementia in Parkinson's disease: nutritional correlates of body compositionArthur Oscar Schelp, Jéssica Emy Komuro, José Eduardo Corrente
and Silvia Justina Papini
36. The role of the gastrointestinal system and gut microbiota in Parkinson's diseaseJade Kenna
and Ryan S. Anderton
37. Swallowing impairment in Parkinson's diseaseMaira Rozenfeld Olchik, Marina Padovani
and Annelise Ayres
38. The Mini Nutritional Assessment (MNA) and applications to Parkinson's diseaseSvetlana Tomic
39. The efficacy of Bacopa monnieri extract in modulating Parkinson's diseaseDr. Ravikumar Hosamani
Part V: Models, modelling and resources 40. 6-hydroxydopamine-induced model of Parkinson's diseaseKatarzyna Kaczy¿ska
and Kryspin Andrzejewski
41. Knockdown transgenic Drosophila and Parkinson's diseaseMarlene Jimenez-Del-Rio
and Carlos Velez-Pardo
42. Neuroprotection in animal models of Parkinson's disease: exploring exercise, sound, and lightJohn Mitrofanis
43. Modeling with the A53T ¿-synuclein model of Parkinson's diseaseThomas Musacchio, James B. Koprich
and Chi Wang Ip
44. Linking the leucine-rich repeat kinase 2 gene, animal models, and Parkinson's diseaseYulan Xiong
and Jianzhong Yu
45. Neuroscience of Parkinson's disease: recommended reading and resourcesRajkumar Rajendram, Vinood B. Patel
and Victor R. Preedy
About the author
Colin R. Martin RN, BSc, MSc, PhD, MBA, YCAP, FHEA, C.Psychol, AFBPsS, C.Sci is Professor of Clinical Psychobiology and Applied Psychoneuroimmunology and Clinical Director of the Institute of Health and Wellbeing at the University of Suffolk, UK. He is a Chartered Health Psychologist and a Chartered Scientist. He also trained in analytical biochemistry, this aspect reflecting the psychobiological focus of much of his research within mental health. He has published or has in press well over 300 research papers and book chapters. He is a keen book author and editor having written and/or edited more than 50 books. These outputs include the prophetic insight into the treatment of neurological disease, Handbook of Behavior, Food and Nutrition (2011), Nanomedicine and the Nervous System (2012), Oxidative Stress and Dietary Antioxidants in Neurological Disease (2020), Zika Virus Impact, Diagnosis, Control and Models (2021), Factors Affecting Neurodevelopment: Genetics, Neurology, Behavior and Diet (2021), Diagnosis and Treatment of Spinal Cord Injury (2022), The Neurobiology, Physiology, and Psychology of Pain (2022) and The Handbook of Lifespan Cognitive Behavioral Therapy: Childhood, Adolescence, Pregnancy, Adulthood, and Aging (2023). Professor Martin is particularly interested in all aspects of the relationship between underlying physiological substrates and behavior, particularly in how these relationships manifest in both acute and chronic psychiatric disorder. He has published original research germane to significant mental health disorders including the areas of schizophrenia, anxiety, depression, self-esteem, alcohol and drug dependency, high secure forensic mental health and personality disorder. He has a keen interest in the impact of postviral illness and is actively involved in clinical research post-Covid pandemic and in particular, the impact of Long Covid on psychological, neurological, physiological and social functioning. He is involved in collaborative International research with many European and Non-European countries.Victor R. Preedy BSc, PhD, DSc, FRSB, FRSPH, FRSC, FRCPath graduated with an Honours Degree in Biology and Physiology with Pharmacology. After gaining his University of London PhD, he received his Membership of the Royal College of Pathologists. He was later awarded his second doctorate (DSc), for his contribution to protein metabolism in health and disease. He is Professor of Clinical Biochemistry (Hon) at King’s College Hospital and Emeritus Professor of Nutritional Biochemistry at King’s College London. He has Honorary Professorships at the University of Hull, and the University of Suffolk. Professor Preedy was the Founding Director and then long-term Director of the Genomics Centre at King’s College London from 2006 to 2020. Professor Preedy has been awarded fellowships of the Royal Society of Biology, the Royal College of Pathologists, the Royal Society for the Promotion of Health, the Royal Institute of Public Health, the Royal Society for Public Health, the Royal Society of Chemistry and the Royal Society of Medicine. He carried out research when attached to the National Heart Hospital (part of Imperial College London), The School of Pharmacy (now part of University College London) and the MRC Centre at Northwick Park Hospital. He has collaborated with international research groups in Finland, Japan, Australia, USA, and Germany. To his credit, Professor Preedy has published over 750 articles, which includes peer-reviewed manuscripts based on original research, abstracts and symposium presentations, reviews and edited books.
